Keros Therapeutics (KROS) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Which has higher valuation & earnings, RXRX or KROS?

Keros Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.84M	36.45	-$463.66M	-$1.78	-2.78
Keros Therapeutics	$3.55M	178.04	-$187.35M	$0.31	50.19

Is RXRX or KROS more profitable?

Keros Therapeutics has a net margin of 8.06% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Keros Therapeutics' return on equity of 2.96% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-1,004.91%	-76.09%	-54.29%
Keros Therapeutics	8.06%	2.96%	2.74%

Do analysts recommend RXRX or KROS?

Recursion Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 41.70%. Keros Therapeutics has a consensus target price of $30.00, indicating a potential upside of 92.80%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Keros Therapeutics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do insiders and institutionals believe in RXRX or KROS?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, RXRX or KROS?

Recursion Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Does the media prefer RXRX or KROS?

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Keros Therapeutics. MarketBeat recorded 14 mentions for Recursion Pharmaceuticals and 9 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.98 beat Recursion Pharmaceuticals' score of 0.78 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Keros Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Keros Therapeutics beats Recursion Pharmaceuticals on 13 of the 16 factors compared between the two stocks.